Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

Greenshoots
Hardiman is seeing 'green shoots of recovery' in the biopharma market • Source: Shutterstock

“We've got geopolitical pressures, macro-economic pressures, interest rates, inflation…” Bradley Hardiman, senior director of business development at Astellas Venture Management, listed the challenges for biopharma going into 2024. “But as an industry, we've always had something that challenges us, and we've always overcome it,” he told In Vivo on the sidelines of the recent BIO-Europe conference in Munich, Germany.

Hardiman was previously an investor at Spex Capital before joining Astellas in April 2022, initially in the company’s internal business...

More from VC Playbook

More from Growth